EP3631448A4 - Detection of par in the csf of patients with parkinson's disease - Google Patents

Detection of par in the csf of patients with parkinson's disease Download PDF

Info

Publication number
EP3631448A4
EP3631448A4 EP18810546.4A EP18810546A EP3631448A4 EP 3631448 A4 EP3631448 A4 EP 3631448A4 EP 18810546 A EP18810546 A EP 18810546A EP 3631448 A4 EP3631448 A4 EP 3631448A4
Authority
EP
European Patent Office
Prior art keywords
parkinson
csf
par
patients
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18810546.4A
Other languages
German (de)
French (fr)
Other versions
EP3631448A1 (en
Inventor
Ted Dawson
Valina DAWSON
Tae-In KAM
Liana ROSENTHAL
Shaida ANDRABI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Priority claimed from PCT/US2018/035614 external-priority patent/WO2018223003A1/en
Publication of EP3631448A1 publication Critical patent/EP3631448A1/en
Publication of EP3631448A4 publication Critical patent/EP3631448A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18810546.4A 2017-06-02 2018-06-01 Detection of par in the csf of patients with parkinson's disease Withdrawn EP3631448A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762514316P 2017-06-02 2017-06-02
PCT/US2018/035614 WO2018223003A1 (en) 2017-06-02 2018-06-01 Detection of par in the csf of patients with parkinson's disease

Publications (2)

Publication Number Publication Date
EP3631448A1 EP3631448A1 (en) 2020-04-08
EP3631448A4 true EP3631448A4 (en) 2021-03-03

Family

ID=69669605

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18810546.4A Withdrawn EP3631448A4 (en) 2017-06-02 2018-06-01 Detection of par in the csf of patients with parkinson's disease

Country Status (2)

Country Link
EP (1) EP3631448A4 (en)
CN (1) CN110998321A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113533725A (en) * 2021-06-23 2021-10-22 上海市肺科医院 Marker for risk of onset and prognosis of pulmonary hypertension and application of marker

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
WO2009152607A1 (en) * 2008-06-16 2009-12-23 Ottawa Hospital Research Institute Methods and kits for diagnosing neurodegenerative disease
US20130022982A1 (en) * 2009-09-14 2013-01-24 Kevin Ka-Wang Wang Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101661032A (en) * 2008-08-29 2010-03-03 生物远景技术有限公司 Biomarker of Parkinson disease
US20170000836A1 (en) * 2013-05-22 2017-01-05 Sirbal Ltd. Prognostic and Diagnostic Methods and Herbal Therapies for Treating Skin Conditions, Autoimmune Diseases, Inflammatory Ailments and Cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
WO2009152607A1 (en) * 2008-06-16 2009-12-23 Ottawa Hospital Research Institute Methods and kits for diagnosing neurodegenerative disease
US20130022982A1 (en) * 2009-09-14 2013-01-24 Kevin Ka-Wang Wang Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018223003A1 *

Also Published As

Publication number Publication date
CN110998321A (en) 2020-04-10
EP3631448A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
IL246564A (en) 3-aryl-1-heterocyclyl-pyrazolo[3,4-d]pyrimidine derivatives and use thereof in the treatment of diseases
PL2968218T3 (en) Combination for the treatment of parkinson's disease
EP3268086A4 (en) Lsd for the treatment of alzheimer's disease
EP3571205A4 (en) Thienopyrimidine derivative and use thereof in medicine
ZA201804079B (en) Lactoferrin for use in the diagnosis or prognosis of alzheimer's disease, or in the diagnosis of parkinson's disease
IL263188B (en) Treatment for parkinson's disease
EP3721890A4 (en) Ophthalmic drug preparation and uses thereof
EP3752840A4 (en) Methods related to parkinson's disease and synucleinopathies
EP3261446A4 (en) Methods and compositions for the treatment or prevention of parkinson's disease
GB201912244D0 (en) Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
EP3710010A4 (en) Use of hm4di in the treatment of seizure disorders
EP3555319C0 (en) Diagnosis of parkinson's disease on the basis of decreased overall translation
EP3534918A4 (en) Exosomes and uses thereof in diseases of the brain
EP3631448A4 (en) Detection of par in the csf of patients with parkinson's disease
EP3713561A4 (en) Pharmaceutical combinations and methods for the treatment of diabetes and associated disorders
EP3109636A4 (en) Biomarker for parkinson's disease and use therefor
EP3565636C0 (en) Use of gut microbiota in the diagnosis of parkinson's disease
EP3606602A4 (en) Deep brain stimulation in early stage parkinson's
EP3162377A4 (en) Use of -asarone in preparing drugs for preventing and treating alzheimer's disease
EP3458058A4 (en) A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases
IL282142A (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
EP3244892A4 (en) Methods of treating motor and movement disorders and side effects thereof associated with parkinson's disease treatments
IL257802A (en) Compositions and methods for the treatment of parkinson's disease
EP3549929A4 (en) Silylated derivatives of reservatrol and the use thereof in neurodegenerative, neurological or inflammatory diseases
EP3359169A4 (en) Diagnosis and treatment of parkinson's disease based on identification and amelioration of liver dysfunction

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210129

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/00 20060101ALI20210125BHEP

Ipc: G01N 33/00 20060101ALI20210125BHEP

Ipc: G01N 33/53 20060101AFI20210125BHEP

Ipc: C12P 21/08 20060101ALI20210125BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20221020